Ninja-family protein 1 Antibody

What is Ninjurin-1 (NINJ1) and why is it important in cell death research?

Ninjurin-1 is a 16 kDa cell-surface protein with two transmembrane regions, with both N and C termini positioned on the outside of the cell. While NINJ1 is dispensable for the initiation of cell death, it plays a crucial role in controlling plasma membrane rupture (PMR) during apoptotic and pyroptotic cell death. This process leads to the non-selective release of pro-inflammatory cytoplasmic contents, collectively known as damage-associated molecular patterns (DAMPs), which activate immune cells and contribute to inflammation. The significance of NINJ1 in cell death research lies in its potential as a therapeutic target to limit inflammation associated with excessive cell death in various disease models .

How does NINJ1 function in the plasma membrane during cell death?

NINJ1 mediates plasma membrane rupture through a process of oligomerization. Under normal conditions, endogenous NINJ1 exists as dimers or trimers (approximately 40 kDa when analyzed by native-PAGE), with some higher-order multimers (160-200 kDa) present in unstimulated cells. During cell death processes such as pyroptosis, necrosis, and post-apoptotic lysis, NINJ1 forms high molecular weight aggregates or clusters within the plasma membrane, ultimately leading to membrane rupture and release of pro-inflammatory cellular contents. This clustering process is a critical step in the execution of lytic cell death pathways .

What factors should be considered when selecting an anti-NINJ1 antibody for research applications?

When selecting an anti-NINJ1 antibody, researchers should consider several factors:

• Target epitope: Different antibodies target different regions of NINJ1. For example, clone D1 recognizes a C-terminal epitope in mouse NINJ1, while clone 25 targets N-terminal residues 22-31. The epitope location can significantly affect antibody function, particularly for inhibitory applications .

• Species specificity: Ensure the antibody recognizes NINJ1 from your species of interest. For instance, clone D1 is specific for mouse NINJ1 and does not inhibit human NINJ1 .

• Functional properties: Some antibodies merely bind NINJ1 (useful for detection), while others can functionally inhibit NINJ1 oligomerization (useful for mechanistic studies). For example, clone D1 potently inhibits NINJ1-dependent PMR, while some commercial antibodies like BD Bioscience clone 50 bind but do not block NINJ1 function .

• Application compatibility: Verify that the antibody has been validated for your intended application (e.g., Western blot, immunocytochemistry, functional studies) .

How can NINJ1 antibodies be used to study plasma membrane rupture in cell death models?

NINJ1 antibodies can be employed in multiple ways to study plasma membrane rupture:

• Inhibition studies: Antagonist antibodies like clone D1 can be added to cell cultures (typically at 1 μg/ml) 15 minutes prior to death stimuli to inhibit NINJ1-dependent PMR. This approach allows researchers to distinguish between upstream cell death signaling and the final execution phase of membrane rupture .

• Membrane integrity assessment: Following antibody treatment, researchers can measure lactate dehydrogenase (LDH) release as a marker of NINJ1-dependent PMR. By comparing LDH release between antibody-treated and untreated cells, the efficiency of NINJ1 inhibition can be quantified .

• Visualization of NINJ1 clustering: Native-PAGE analysis can be used to visualize NINJ1 oligomerization in response to cell death stimuli and its inhibition by antibody treatment. In this approach, the shift of NINJ1 signal to high molecular weight aggregates indicates clustering, while prevention of this shift by antibody treatment confirms successful inhibition .

What are the validated cell death models for studying NINJ1 antibody effects?

Several cell death models have been validated for studying NINJ1 antibody effects:

• Pyroptosis: TLR2 agonist (e.g., Pam3CSK4) primed macrophages followed by nigericin stimulation to activate NLRP3- and GSDMD-dependent pyroptosis .

• Apoptosis: Treatment with TNF plus cycloheximide or venetoclax to induce caspase-dependent apoptosis .

• Necrosis: Treatment with pneumolysin to induce necrotic cell death .

• Necroptosis: TNF plus pan-caspase inhibitor zVAD to induce necroptosis (though NINJ1 is not required for membrane rupture in this pathway) .

These models can be established in various cell types, including mouse bone marrow-derived macrophages (BMDMs), human monocyte-derived macrophages (hMDMs), and cell lines overexpressing NINJ1 .

What methods are recommended for validating the specificity of anti-NINJ1 antibodies?

To validate the specificity of anti-NINJ1 antibodies, researchers should consider:

• Genetic controls: Include NINJ1-knockout cells as negative controls. For example, comparing antibody binding or functional effects between wild-type and Ninj1−/− cells can confirm specificity .

• Epitope mapping: Determine the recognized epitope using deletion mutants or alanine scanning mutagenesis. For instance, the D1 antibody was shown not to bind NINJ1 with mutations at residues 147-150 (147VAPR>A 147AAAA), indicating these residues are critical for antibody recognition .

• Cross-reactivity testing: Test antibody binding against related proteins (e.g., NINJ2) or against NINJ1 from different species to establish specificity boundaries .

• Functional validation: For inhibitory antibodies, confirm that their effects phenocopy those of NINJ1 genetic deletion or silencing. For example, both NINJ1 knockout and clone D1 treatment should reduce PMR to similar levels in relevant cell death models .

How can NINJ1 antibodies be used to investigate the molecular mechanism of membrane rupture?

For advanced mechanistic studies, NINJ1 antibodies can be employed to:

• Isolate and characterize NINJ1 oligomers: Immunoprecipitation with non-inhibitory antibodies can help isolate native NINJ1 complexes for structural and biochemical characterization .

• Visualize NINJ1 distribution: Immunofluorescence using non-inhibitory antibodies can reveal the spatial distribution and clustering of NINJ1 during cell death processes .

• Prevent NINJ1 oligomerization: Electron microscopy studies showed that inhibitory antibodies like clone D1 prevent NINJ1 from forming oligomeric filaments. This approach can help dissect the structural requirements for NINJ1-dependent membrane rupture .

• Distinguish between NINJ1-dependent and independent membrane rupture: By comparing cellular responses with and without inhibitory antibodies, researchers can determine which aspects of cell death depend specifically on NINJ1-mediated membrane rupture .

What is the relationship between NINJ1 inhibition and glycine cytoprotection in cell death models?

The relationship between NINJ1 and glycine represents an important area of research:

• Phenotypic similarities: NINJ1 knockout or silencing functionally and morphologically phenocopies glycine cytoprotection in various forms of lytic cell death. Both interventions allow for IL-1β secretion through the gasdermin D pore while preventing final membrane lysis .

• Mechanism of glycine protection: Glycine treatment prevents NINJ1 clustering within the plasma membrane without affecting upstream programmed cell death signaling. This suggests that glycine's cytoprotective effect is mediated, at least in part, through inhibition of NINJ1 oligomerization .

• Biochemical evidence: In native-PAGE analysis, glycine treatment completely abrogates the shift of endogenous NINJ1 to high molecular weight aggregates during pyroptosis, necrosis, and apoptosis induction. This provides direct biochemical evidence linking glycine's protective effect to NINJ1 clustering inhibition .

What are common pitfalls in NINJ1 antibody-based experiments and how can they be addressed?

Researchers may encounter several challenges when working with NINJ1 antibodies:

• Species-specific recognition: Some antibodies are species-specific, such as clone D1 which inhibits mouse but not human NINJ1. Researchers should verify species compatibility before conducting experiments .

• Epitope accessibility: NINJ1's membrane topology with both N and C termini outside the cell means that epitope accessibility may vary depending on NINJ1's conformation or interaction partners. Using antibodies targeting different epitopes can help address this issue .

• Functional vs. binding capability: Not all NINJ1-binding antibodies inhibit function. For example, BD Bioscience clone 50 and a NINJ1 26-37 peptide failed to block nigericin-induced PMR despite being marketed as NINJ1 blockers. Functional validation is essential .

• Concentration optimization: The efficacy of inhibitory antibodies depends on appropriate dosing. For clone D1, 1 μg/ml was found effective for in vitro studies. Researchers should perform dose-response studies to determine optimal concentrations for their specific experimental systems .

How should researchers interpret different outcome measures in NINJ1 antibody experiments?

When interpreting NINJ1 antibody experiment results, researchers should consider:

How can researchers distinguish between NINJ1-specific effects and off-target antibody effects?

To distinguish between specific and off-target effects:

• Use genetic controls: Compare antibody effects in wild-type and NINJ1-knockout or knockdown cells. Specific antibodies should show effects in wild-type but not in knockout cells .

• Test Fab fragments: The antigen-binding fragment (Fab) of inhibitory antibodies like clone D1 can prevent PMR independently of Fc receptor binding, confirming direct NINJ1 targeting rather than Fc-mediated effects .

• Examine cell death pathway specificity: NINJ1 inhibition should block PMR in pyroptosis and apoptosis but not in necroptosis. This pattern can help confirm NINJ1-specific effects .

• Use multiple antibody clones: Different antibodies targeting distinct NINJ1 epitopes should produce consistent results if the effects are NINJ1-specific .

What evidence supports the therapeutic potential of NINJ1 antibodies in disease models?

Emerging evidence suggests therapeutic potential for NINJ1 antibodies:

• Hepatitis models: Treatment with clone D1 antibody attenuated inflammation in acetaminophen-induced liver injury and ConA-mediated immune-mediated hepatitis models. In these contexts, NINJ1 inhibition reduced serum ALT levels, a marker of liver damage .

• Chronic inflammation: The effect of NINJ1 blockade in settings of chronic inflammation, where protracted DAMP release exacerbates pathology, remains an area of active investigation. Previous studies suggest that Ninj1 deficiency attenuates mouse models of pulmonary fibrosis and multiple sclerosis .

• Limitations: Current antibody-based approaches have pharmacokinetic limitations. Researchers were unable to sustain serum levels of clone D1 long-term by repeat dosing, suggesting that improved reagents with better pharmacokinetic properties will be needed for chronic disease models .

What are the current limitations of anti-NINJ1 antibodies for in vivo applications?

Several limitations affect the translation of anti-NINJ1 antibodies to in vivo applications:

• Pharmacokinetic constraints: Current antibodies like clone D1 have limited half-lives in vivo, making it difficult to maintain therapeutic levels with repeated dosing .

• Species-specificity: Many validated inhibitory antibodies are species-specific (e.g., clone D1 works in mice but not humans), complicating translational research .

• Tissue penetration: As with many antibody therapeutics, ensuring adequate penetration into affected tissues remains challenging .

• Dosing optimization: Optimal dosing regimens for different disease models are still being established. Initial studies used 200 μg (10 mg/kg) of clone D1 administered intravenously, but this may require optimization for different disease contexts .

How can CRISPR-based approaches complement antibody studies in NINJ1 research?

CRISPR-based approaches offer powerful complementary tools:

• Genetic validation: CRISPR-Cas9 knockout of NINJ1 provides an essential control to validate antibody specificity and effectiveness. For example, CRISPR-Cas9 with guide RNA targeting the Ninj1 sequence GCCAACAAGAAGAGCGCTG has been successfully used to generate NINJ1-knockout cells .

• Domain mapping: CRISPR-based precise editing of specific NINJ1 domains can help identify critical regions for antibody binding and function, facilitating the development of more effective inhibitory antibodies .

• In vivo models: CRISPR-engineered mouse models lacking NINJ1 provide valuable tools to compare with antibody-treated wild-type mice, helping distinguish between developmental and acute effects of NINJ1 inhibition .

What alternative approaches exist for inhibiting NINJ1-mediated membrane rupture beyond antibodies?

Besides antibodies, researchers can consider:

• RNA interference: siRNA targeting NINJ1 (such as pooled siRNAs HSS107188, HSS107190, HSS181529) has been successfully used to knockdown NINJ1 in human macrophages. This approach provides a complementary genetic method to validate antibody findings .

• Small molecules: Glycine has been identified as an endogenous inhibitor of NINJ1 clustering. This opens the possibility of developing small molecule mimetics that could prevent NINJ1 oligomerization with potentially better pharmacokinetic properties than antibodies .

• Peptide-based inhibitors: Given that specific regions of NINJ1 are essential for its oligomerization, peptides derived from these regions might competitively inhibit NINJ1 clustering and subsequent membrane rupture .

• Extracellular vesicle expression: Expression of full-length NINJ1 in extracellular vesicles has been used experimentally and could potentially be adapted for therapeutic applications .